Braveheart Bio (BRVE) is trading up at $21.48 (+2.09%), as of the latest quote. It operates in the sector.
| Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|
| Income statement | ||||
| Operating income | −$99.0K | −$381.0K | −$15.0M | −$15.9M |
| Net income | −$99.0K | −$381.0K | −$14.3M | −$15.0M |
| EPS (diluted) | −$0.20 | −$0.14 | −$2.10 | −$2.51 |
| Balance sheet | ||||
| Cash and equivalents | — | $2.00K | — | $122.8M |
| Total assets | — | — | — | $127.0M |
| Total liabilities | — | — | — | $9.34M |
| Shareholders' equity | −$99.0K | −$477.0K | −$78.4M | −$95.9M |
From Braveheart Bio's 10-Q filings with the SEC. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
No recent news mentioning Braveheart Bio in our feed yet.